4 results about "Increase blood pressure" patented technology

This invention discloses an environmental parameter sensing and adaptive adjustment system and method based on a photoconductive film. It integrates six-dimensional environmental sensors—light intensity, ultraviolet radiation, temperature, humidity, air pressure, and air quality—at the edge of the photoconductive film, and utilizes the film's directional light guidance and stray light filtering mechanisms to reduce environmental interference. The system includes an environmental sensing module, an environmental parameter processing module, a health data interface module, a correlation analysis module, an adaptive adjustment module, and an environmental early warning module. The correlation analysis module has preset environmental-health correlation patterns such as low temperature-increased blood pressure, high humidity-decreased blood oxygen, high ultraviolet radiation-skin health, poor air quality-respiratory diseases, and sudden changes in air pressure-headaches and joint pain, set based on clinical research data. The adaptive adjustment module pairs with smart home devices through a unified identity authentication center, sending control commands via Wi-Fi / Bluetooth / infrared to automatically adjust air conditioners, humidifiers, dehumidifiers, air purifiers, and lighting according to environmental parameters. The environmental early warning module supports single-indicator early warning, correlation early warning, trend early warning, and seasonal disease early warning, with customizable thresholds. The multi-environmental data fusion module uses weighted averaging and the 3σ principle for anomaly removal, integrating data from multiple devices such as mobile phones, watches, vehicles, and smart home devices. The sensors are automatically calibrated daily using meteorological bureau data, with the calibration process simultaneously linked to health data. This invention solves the problems of scattered environmental sensing devices, disconnect from health data, and inability to proactively adjust, serving as the infrastructure for intelligent health management.

Provided herein are methods of stabilizing blood pressure in severe sepsis / septic shock and other types of distributive shock using TRPV1 agonists. Also provided are pharmaceutical formulations for increasing blood pressure in septic shock the formulation including at least one TRPV1 agonist in a dosage form for parenteral administration, wherein the TRPV1 agonist is selected from capsaicin, daphnane TRPV1 agonists, vanillotoxin, N-oleoyl dopamine, N-arachidonyl dopamine, BrP-LPA, and derivatives and analogues thereof. Also provided are TRPV1 agonists co-lyophilized with adrenergic agonists and / or angiotensins in a dosage form for reconstitution and parenteral administration.

The invention provides a brain-computer interface-based hypertensive drug dynamic monitoring system and a brain-computer interface-based hypertensive drug dynamic monitoring method, designs a novel hypertensive drug dynamic monitoring mechanism, and analyzes the drug effect by mixing the electroencephalogram signal, the blood pressure signal and the drug taking time to form a multi-modal signal. A series of optimization settings continue to be matched from the aspect of details, so that through multi-modal fusion, dynamic modeling, personalized optimization and clinical closed loop, the system comprehensively surpasses the prior art in the aspects of monitoring dimension, decision depth and function integration, and through collaborative analysis of nerve-blood pressure-autonomic nerve, the accuracy of the system is improved. The normal form transformation of hypertension treatment from symptomatic administration to nerve-body fluid-blood vessel coordinated regulation is promoted, and the accuracy, individuation and safety of hypertension drug monitoring are remarkably improved.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.